Chronic Myeloid Leukemia
Conditions
Interventions
TKI de-escalation/intermittence-cessation group (the strategy was chosen according to patients' and guardians' will):NA
Sponsors
Beijing Childrens Hospital,Capital Medical University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Patients who are 18 years or younger, and have a diagnosis of CML chronic phase; 2. Patients who have been taking TKI for = 36 months and have not experienced treatment failure (according to the definitions in ELN recommendations); 3. Patients must have a history of stable molecular response, defined as MR4 for =24 months, as documented by =5 separate tests; 4. Patients and/or their guardian are willing to give their consent to participate to the study.
Exclusion criteria
Exclusion criteria: 1. A history of blast crisis or accelerated phase; 2. Previous tyrosine kinase inhibitor resistance; 3. Patient has received hematopoietic stem cell transplantation or immunotherapy (including interferon); 4. There are two or more significant abnormalities in the blood routine; 5. Another malignant disease; 6. Patients complicated with any other diseases or psychiatric disease that could affect their safety and compliance, informed consent, participation, follow-up or interpretation of results.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Overall;The rate of re-establishing MMR in children or adolescents who lost MMR afte TKI de-escalation, intermittence or cessation;Progression-free survival; | — |
Primary
| Measure | Time frame |
|---|---|
| ?Z of Body Mass Index;Major Molecular Response;?Z of weight;Treatment-free remission;?Z of height; | — |
Countries
China
Contacts
Public ContactHuyong Zheng
Beijing Childrens Hospital,Capital Medical University
Outcome results
None listed